| Key Investigators |
|
 |
Timothy Cloughesy M.D. Principal Investigator
Dr. Cloughesy is Program Director of the UCLA Neuro-Oncology program. Their aim is to provide a Multi-disciplinary
approach to patients
suffering from neuro-oncologic diseases such as primary malignant brain tumors,
primary malignant spinal cord tumors, metastatic brain tumors, carcinomatous
meningitis, epidural spinal cord compression, paraneoplastic disorders and
neurologic complications of cancer and its treatment. This program utilizes
experts in the fields of Neurology, Neuro-surgery, Medical Oncology, Radiation
Oncology, Neuro-Pathology, Neuro-Imaging, Neuropsychiatry, Neuro-psychology, and
social work to provide the most advanced and individualized care. This team of
experts are leaders not only in defining state of the art care but are also
intimately involved in the design of novel clinical trials including,
antiangiogenesis agents, signal transduction inhibitors, novel radiation
sensitizers, immune based therapies, gene therapies, biologic agents and blood
brain barrier delivery systems.
|
|
Stan Nelson M.D. Principal Investigator
The Nelson Lab at UCLA uses genomic approaches towards the study of complex human
diseases. They have several research programs to discover genetic variants that
underlie Attention Deficit and Hyperactivity Disorder, Autism, and Vertigo. These
projects use linkage, linkage disequilibrium and association approaches in
hundreds of affected sibling pair families. The laboratory also studies the
genetic causes of glioblastoma, the most common and lethal form of primary brain
cancer, using large scale gene expression analysis, alternative splicing
analysis and chromosomal loss information, and is developing bioinformatic
approaches to use this information to identify and prioritize novel therapeutic
targets. They are also developing novel technologies based on shape encoding to
allow highly multiplexed cellular and molecular assays. All of these projects
require a host of integrated bioinformatics approaches which rely on a large and
growing repository of gene expression, sequence, and polymorphism information
from human and mouse tissues.
|
|
Michael Quinn Product Developer
Quinn brings 10 years of experience building medical informatics systems for the brain cancer community and currently serves as CEO of SiliconMED, a privately held company whose aim is to deliver software tools that accelerate the process of new discovery and improve the performance of clinical operations. |
|
Linda Liau M.D.,Ph.D. Neurosurgeon & Tissue Banking
Dr. Linda M. Liau is a neurosurgeon and Associate Professor of Neurosurgery at the UCLA School of Medicine. She is Co-Director of the Comprehensive Brain Tumor Program and Director of Neurosurgical Oncology at the UCLA Medical Center in Los Angeles. |
|
Paul Mischel M.D. Neuro-Pathology
Dr. Mischel is a board certified neuropathologist with expertise in signal transduction biology. His laboratory has expertise in quantitative analysis of signal transduction pathways, stem-cell related pathways, and gene expression networks in clinical samples. His laboratory focuses on the development and application of molecularly targeted therapies for glioblastoma and on the application of emerging technologies to identify the patients most likely to benefit from these new treatments. |
|
* Special thanks to Yohan Lee for making raw expression data readily available and to Jun Dong for statistical guidance in calculating p-values for multiple groups.
|
|
